News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Flip Side: What Valeant Pharmaceuticals International (VRX) Gets Right About R&D



6/17/2014 7:39:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

This morning, hoping to call into question its would-be acquirer, Valeant, Allergan issued a press release quoting the global head of M&A at Morgan Stanley, a blogging Australian hedge fund manager, and me. It was not the beginning of a joke where we all walk into a bar. Tomorrow, Valeant is hosting a conference call to try to rebut what it says are misleading questions about its business model made by Allergan and others.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES